The federal agency restructured its flu and COVID-19 units into a unified Influenza and Respiratory Viruses Division (IRVD).
RT’s Three Key Takeaways
- Division Consolidation: The Centers for Disease Control and Prevention reorganized its National Center for Immunization and Respiratory Diseases by combining the Influenza Division and the Coronavirus and Other Respiratory Diseases Division into a single operational unit.
- Core Responsibilities: The newly established Influenza and Respiratory Viruses Division oversees laboratory surveillance, viral detection, disease modeling, public health interventions, and international viral threats.
- Official Implementation: Approved by the secretary of the Department of Health and Human Services on August 18, 2026, the federal reorganization officially took effect on September 4, 2026.
The CDC has reorganized the National Center for Immunization and Respiratory Diseases (NCIRD) by consolidating its primary viral disease branches, according to a federal notice published by the Department of Health and Human Services (HHS).
Under the reorganization, the agency merged the Influenza Division and the Coronavirus and Other Respiratory Diseases Division to establish the unified Influenza and Respiratory Viruses Division (IRVD). The restructuring was approved on August 18, 2026, by Robert F Kennedy Jr, secretary of the Department of Health and Human Services, and took effect on September 4, 2026, the notice stated.
Structure and Mission of the New Division
According to the federal notice, the IRVD is tasked with preventing disease, disability, and death resulting from seasonal, epidemic, and pandemic respiratory viral illnesses. The division monitors infection patterns, delivers technical assistance to state and local health partners, identifies viral properties to improve diagnostic tools and medical countermeasures, designs intervention strategies, and uses research findings to guide prevention policies.
The newly established division comprises six structural components:
- Office of the Director: Directs overall division strategy, oversees laboratory quality and safety protocols, manages external partnerships, and coordinates public communications and informatics.
- Virology and Laboratory Surveillance Branch: Performs antigenic, phenotypic, structural, and genetic evaluations of human and animal viruses, analyzes risks for novel and emerging pathogens, offers technical guidance on vaccine virus selection, and supports diagnostic laboratories.
- Respiratory Virus Detection and Immunology Branch: Evaluates host immune responses, develops laboratory surveillance methods, conducts pandemic risk assessments, and supplies technical expertise during respiratory outbreak investigations.
- Surveillance, Epidemiology, and Modeling Branch: Leads sentinel and national surveillance programs, generates predictive models to assess disease severity and trends, and assists public health departments with data visualization and outbreak response.
- Public Health Interventions Branch: Develops and evaluates prevention initiatives, including vaccination, treatments, and non-pharmaceutical interventions, while conducting economic and epidemiologic analyses on disease burden.
- Emerging Viral Respiratory Threats Branch: Directs international surveillance programs, tracks emerging viral threats outside the US, and coordinates global outbreak response and preparedness efforts.
Implications for Healthcare and Respiratory Care
The consolidation aligns surveillance, laboratory testing, and clinical intervention development under a single management framework. For healthcare organizations and respiratory care clinicians, the integration of flu and coronavirus operations is intended to streamline viral tracking data, diagnostic recommendations, and clinical guidance across overlapping respiratory illness seasons.
The agency confirmed that existing delegations of authority for personnel in the affected divisions will remain in effect through the restructuring process.
